Grade My Investments
HomeFree Stock Grades › CRVS

Corvus Pharmaceuticals, Inc. (CRVS) Stock Grade

CRVS · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$608.0M
P/E Ratio
Revenue Growth (YoY)
0.0%
Net Margin
0.0%
Return on Equity
Dividend Yield
None

About Corvus Pharmaceuticals, Inc.'s fundamentals

Corvus Pharmaceuticals is a biotechnology company with a market capitalization of $608.0 million that reported zero year-over-year revenue growth in its latest period. The company posted a net loss in its most recent annual statement, reflected in a net margin of 0.0%, and does not currently pay a dividend. Standard profitability metrics like P/E ratio and return on equity are not applicable due to the company's loss-making status.

Track CRVS free — no credit card required. Live grade + monthly AI report →